A 17-year-old patient named Elizabeth Dashiell arrived at New York Hospital in 1890 with an aggressive bone tumor in her hand, sparking a search for new cancer treatments that defined William Coley’s career. After her death, he pioneered the study of cancer immunotherapy by investigating the role of infection in tumor remission.
Early Career and Education
Born in Saugatuck, Westport, in 1862, William Bradley Coley pursued a degree in Classics at Yale University before graduating from Harvard Medical School in 1888. Following his education, he began a surgical internship at New York Hospital. His clinical approach shifted fundamentally after treating Dashiell, whose forearm amputation failed to prevent widespread metastasis. Distressed by the limitations of surgical intervention, Coley transitioned into the role of a clinician-scientist.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →The Origin of Coley’s Toxins
Coley’s research led him to a case involving Fred Stein, a patient whose neck tumor reportedly vanished following a bout of erysipelas. This observation prompted Coley to investigate if stimulating the immune system could destroy malignant cells. In 1891, he injected a patient named Zola with live Streptococcus bacteria. While the tumor dissolved, the method was inherently dangerous. Coley eventually developed a mixture of dead Streptococcus pyogenes and Serratia marcescens, which reduced mortality risks compared to the live infection approach.
Obsolescence and Radiation
By 1901, radiation therapy emerged as a promising alternative, offering immediate pain relief and tumor destruction. Although Coley initially experimented with x-ray machines, he concluded the therapy was localized and non-curative. Scientific peers, including James Ewing, argued that the toxin mixture was unpredictable, labor-intensive, and lacked reproducibility. As radiation technology gained widespread clinical adoption, the use of Coley’s vaccine began to decline.
Regulatory Impact and Legacy
Coley’s toxins remained in use globally until the 1962 Kefauver Harris Amendment required the mixture to be recertified as a new drug by the Food and Drug Administration. This regulatory change effectively restricted the treatment to experimental clinical trials. Today, organizations like Cancer Research UK advise against using these toxins as an adjunct or replacement for standard treatments due to the lack of evidence regarding efficacy and the potential for serious health risks.
Fast facts
- Born: 1862, Westport, Connecticut
- Died: 1936, New York City
- Education: Yale University and Harvard Medical School
- Known as: Father of Cancer Immunotherapy
- Key Treatment: Coley’s toxins
- Award: Honorary Fellow of the Royal College of Surgeons (1935)
- Professional Category: Physician, surgeon, and oncologist
Questions readers ask
What were Coley’s toxins?
A mixture of dead Streptococcus pyogenes and Serratia marcescens intended to stimulate an immune response against tumors.
Why did the use of the toxins stop?
The 1962 Kefauver Harris Amendment required the treatment to be labeled a new drug, limiting its use to experimental trials.
Achievements
- honorary Fellow of the Royal College of Surgeons — 1935
